Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical firm, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. CEO Rahul Ballal, Ph.D., will partake in a Fireside Chat at 3:40 p.m. ET, focusing on the company’s advancements in rare hemoglobin disorders. Imara is progressing with tovinontrine (IMR-687), a treatment for sickle cell disease and beta-thalassemia in Phase 2b trials, and plans to initiate another trial in heart failure (HFpEF) by Q2 2022. Further details available on Imara’s website.

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET. 

A replay of the webcast will be archived on the “Events and Presentations” section of Imara’s website. 

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment in Phase 2b clinical trials for sickle cell disease and beta-thalassemia. Imara expects to initiate a Phase 2 clinical trial of tovinontrine in heart failure with preserved ejection fraction (HFpEF) in the second quarter of 2022. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What will Imara discuss at the SVB Leerink Global Healthcare Conference on February 17, 2022?

Imara will discuss advancements in their clinical-stage biopharmaceuticals, including updates on tovinontrine and other therapies.

Who is participating in the Fireside Chat at the Imara event?

Rahul Ballal, Ph.D., President and CEO of Imara, will participate in the Fireside Chat.

What is the purpose of Imara's participation in the SVB Leerink Global Healthcare Conference?

Imara aims to showcase their novel therapeutics aimed at treating rare hemoglobin disorders and to provide updates on clinical trials.

When does Imara expect to begin the Phase 2 clinical trial for tovinontrine in heart failure?

Imara expects to initiate the Phase 2 clinical trial of tovinontrine in heart failure with preserved ejection fraction in Q2 2022.